Edgestream Partners L.P. Purchases New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Edgestream Partners L.P. purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 12,880 shares of the medical research company's stock, valued at approximately $2,378,000.

A number of other large investors also recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in Charles River Laboratories International during the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. increased its stake in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp increased its stake in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Charles River Laboratories International by 3.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $176.20 on Monday. The firm has a 50 day moving average of $169.15 and a 200 day moving average of $185.63. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $9.01 billion, a price-to-earnings ratio of 1,174.68, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77.

Remove Ads

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The company's revenue for the quarter was down 1.1% on a year-over-year basis. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

CRL has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. TD Cowen lifted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. UBS Group reiterated a "neutral" rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group reduced their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $198.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.